• 1
    Mignot G. Drug trials in epilepsy. BMJ 1996 313.1158.
  • 2
    Temple R. Government viewpoint on clinical trials. Drug Inform J 1982; 1 107.
  • 3
    Leber P. Hazards of inference: the active control investigation. Epilepsia 1989; 30 (suppl l): S57–63.
  • 4
    Guidelines for the Clinical Evaluation of Antiepileptic Drugs (1989). Epilepsia 1989; 30 4006.
  • 5
    Mattson RH., Cramer JA., Collins JF., et al. Comparison of carba-mazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313 14551.
  • 6
    Mattson RH., Cramer JA., Collins JF., et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327 76571.
  • 7
    Devinsky O. Psychosocial and behavioural function in epilepsy. In: PorterR., ChadwickD. The epilepsies II., Boston : Butterworth Heinemann, 1997; 34764.
  • 8
    Jacoby A., Baker GA., Steen N., Potts P., Chadwick D. The clinical course of epilepsy and its psychosocial correlates: findings from a UK Community Study. Epilepsia 1996; 37 14861.
  • 9
    Heller AJ., Stewart J., Hughes E., et al. Comparative efficacy and toxicity of phenobarbital, phenytoin, carbamazepine and valproate in adults and children with newly diagnosed previously untreated epilepsy. J Neurol Neurosurg Psychiatry 1995; 58 4450.
  • 10
    Chadwick D., Anhut H., Murray G., Greiner M., Alexander J. and the International Gabapentin Monotherapy Study Group (945-077). Gabapentin monotherapy in patients with newly-diagnosed epilepsy: results of a double-blind, fixed dose study comparing three dosages of gabapentin and open-label carbamazepine [Abstract]. Epilepsia 1997; 38 (suppl 3): 34.
  • 11
    Jones B., Jarvis P., Lewis J. A., et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313 369.
  • 12
    Henry D., Hill S. Comparing treatments: comparison should be against active treatments rather than placebos. BMJ 1995 310: 1279.
  • 13
    Rothman KJ., Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994 331:394-8.
  • 14
    Declaration of Helsinki IV. Quoted by Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994;331:394.
  • 15
    Hill AB. Cited by Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994, 331:396.
  • 16
    Bourgeois B., Leppik IE, Sackellares JC, et al. Felbamate: a double blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993;43:6936.
  • 17
    Faught RE, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial onset seizures: an active-control trial. Neurology 1993;43:68892.
  • 18
    Sachdeo R., Kramer LD, Rosenberg A., Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992;32:38692.
  • 19
    Sachdeo RC, Reife RA, Lim P., Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997;38:294300.
  • 20
    First Seizure Trial Group (FIR.S.T. Group). Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 1993;43:47883.
  • 21
    Medical Research Council Antiepileptic Drug Withdrawal Study Group (D. Chadwick, clinical co-ordinator). Randomized study of antiepileptic drug withdrawal in patients in remission. Lancet 1991;337:117580.